IPO
NOXXON Pharma N.V. hereby announces the launch and terms of a share capital increase with shareholders’ preferential rights for an amount of up to € 3.9 million.
Global Blood Therapeutics, Inc. announced an agreement to sell approximately $200.0 million in shares of its common stock in a registered underwritten public offering.
The Management Board of MagForce AG has resolved and successfully completed, with the approval of the Supervisory Board, on basis of the authorization provided for in the Company’s articles of association, an increase of the registerd share capital of the Company from currently EUR 26,463,802.00 to EUR 27,640,274.00 by issuing 1,176,472 new no-par value bearer shares under exclusion of the shareholders’ statutory subscription rights.
Mirati Therapeutics, Inc. announced that it has commenced an underwritten public offering of shares of its common stock.
Domain Therapeutics announces the appointment of world-renowned GPCR and drug discovery and development experts to its Scientific Advisory Board (SAB): Pr. Silvio Gutkind, Pr. Morley Hollenberg and Pr. Brigitte Kieffer.
Medtronic plc announced the commencement of two cash tender offers by its wholly-owned indirect subsidiaries, Medtronic, Inc., Medtronic Global Holdings S.C.A. and Covidien International Finance S.A. (“CIFSA” and, together with Medtronic, Inc.
The board of directors of Medtronic plc approved an 8 percent increase in its quarterly cash dividend, raising the quarterly amount to $0.54 per ordinary share.
Galapagos NV announces a share capital increase arising from warrant exercises.
This week marked initial public offering news from six biopharma companies. Here’s a look.
Lonza reports restated 2018 financials for sales, CORE EBITDA and CORE EBIT
PRESS RELEASES